The biggest losers of the session on the Wall Street include AnaptysBio, Inc. (NASDAQ:ANAB), which fell -2.28 points or -4.47% to trade at $48.72 as last check. The stock closed last session at $51 and sets an active trading volume day with a reported 297027 contracts so far this session. ANAB shares had a relatively better volume day versus average trading capacity of 277.46 thousand shares, but with a 26.68 million float and a -1.94% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for ANAB stock indicates that the average analyst price target is $110.78 per share. This means the stock has a potential increase of 127.38% from where the ANAB share price has been trading recently which is between $47.734 and $54.19. There are some brokerage firms that offer lower targets than the average, with one of them, even setting their price target at $74.
The shorts are climbing into AnaptysBio, Inc. (ANAB) stock. The latest set of short interest data was released on 31 July 2019, and the numbers show a rise in short interest in ANAB shares. While short interest still represents only 15.64% of ANAB’s float, the number of shares shorted have risen by 51548. The number of shares shorted advanced to 4223902 shares, up from 4172354 shares during the preceding fortnight. With average daily trading volumes at 197665 shares, days to cover decreased to about 22.19621 days. The most recent news story about the stock that appeared in Yahoo Finance‘s news section was titled “AnaptysBio Prepares for a Potential Gear Shift” and dated August 10, 2019.
During the recent trading session for AnaptysBio, Inc. (NASDAQ:ANAB), the company witnessed their stock drop by $-1.39 over a week and tumble down $-6.94 from the price 20 days ago. When compared to their established 52-week high of $110, the high they recorded in their recent session happens to be lower. Their established 52-week high was attained by the company on 09/24/18. The recent low of $47.73 stood for a -55.71% since 08/09/19, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 0 is also allocated to the stock. Since the beta is less than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to.
Looking at the current readings for AnaptysBio, Inc., the two-week RSI stands at 31.71. This figure suggests that ANAB stock, for now, is neutral, meaning that the shares are stable in terms of price movement. The stochastic readings, on the other hand, based on the current ANAB readings is similarly very revealing as it has a stochastic reading of 29.44% at this stage. This figure means that ANAB share price today is being overbought.
Technical chart claims that AnaptysBio, Inc. (ANAB) would settle between $54.22/share to $57.43/share level. However, if the stock price goes below the $47.76 mark, then the market for AnaptysBio, Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $44.52 for its downside target. The stock is currently in the red zone of MACD, with the indicator reading -1. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.
Analysts at Stifel lowered their recommendation on shares of ANAB from Buy to Hold in their opinion released on June 21. Credit Suisse analysts have lowered their rating of AnaptysBio, Inc. (NASDAQ:ANAB) stock from Outperform to Neutral in a separate flash note issued to investors on June 21. Analysts at H.C. Wainwright, made their first call for the equity with a Buy recommendation, according to a research note that dated back to December 20.
ANAB equity has an average rating of 2, with the figure leaning towards a bullish end. 10 analysts who tracked the company were contacted by Reuters. Amongst them, 3 rated the stock as a hold while the remaining 7 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 7 analysts rated AnaptysBio, Inc. (NASDAQ:ANAB) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.
Moving on, ANAB stock price is currently trading at 0X forward 12-month Consensus EPS estimates, and its P/S ratio is 55.97 while for the average stock in the same group, the multiple is 49.47.
AnaptysBio, Inc. (ANAB)’s current-quarter revenues are projected to climb by nearly 53.32% to hit $7.67 million, based on current Zacks Consensus Estimate. The firm’s full-year revenues are expected to expand by over 73.32% from $5 million to a noteworthy $8.67 million. At the other end of the current quarter income statement, AnaptysBio, Inc. is expected to see its adjusted earnings surge by roughly -36.36% to hit $-0.9 per share. For the fiscal year, ANAB’s earnings are projected to climb by roughly -50.4% to hit $-3.76 per share.